Ardelyx, Inc. (ARDX) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $6.91: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 7.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Below-average business quality.
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with... Read more
Sell if holding. Engine safety override at $6.91: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 7.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 64, MACD bullish. Score 5.7/10, moderate confidence.
Passes 6/6 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity no date, semi cycle peak clear). Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers·1 ceiling hit
Unprofitable operations — net margin -15.1%. Quality floor flags this regardless of sector context.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $6.91: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 7.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 64, MACD bullish. Prior stop was $6.33. Score 5.7/10, moderate confidence.
Take-profit target: $14.31 (+110.3% upside). Prior stop was $6.33. Stop-loss: $6.33.
Quality below floor (3.7 < 4.0).
Ardelyx, Inc. trades at a P/E of N/A (forward 11.2). TrendMatrix value score: 8.7/10. Verdict: Sell.
18 analysts cover ARDX with a consensus score of 4.5/5. Average price target: $16.
What does Ardelyx, Inc. do?Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and...
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.